The Effects of Antibiotic Combinations on Stem Cells

The Effects of Antibiotic Combinations on Mesenchymal Stem Cells Derived From Apical Papilla

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04713436

Enrollment

Registered

2021-01-19

Start date

2014-01-01

Completion date

2017-02-01

Last updated

2021-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-Bacterial Agents, Stem Cells

Brief summary

The purpose of this study was to evaluate the indirect effects of antibiotic combinations. SCAP viability, proliferation and apoptosis of the cells were evaluated. Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.

Detailed description

The purpose of this study was to evaluate the indirect effects of triple (TAP- ciprofloxacin, metronidazole and minocycline), double (DAP- ciprofloxacin and metronidazole) and modified triple antibiotic pastes (mTAP- ciprofloxacin, metronidazole and cefaclor) on mesenchmal stem cells derived from apical papilla (SCAP). SCAP were isolated from the impacted third molar teeth of the young adults. TAP, DAP and mTAP treatment (14-day medication and 28-day medication) were applied on SCAP and viability, proliferation and apoptosis of the cells were evaluated after four weeks. Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.

Interventions

DRUGDifferentiation Markers

Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to 22 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with open apex third molar teeth for extraction indication

Exclusion criteria

* Patients with mature apex third molar teeth for extraction indication

Design outcomes

Primary

Measure	Time frame	Description
Measurment of Cell Viability and Apoptosis	1 year	To evaluate cell viability and apoptosis MuseCell Analyzer Count and Viability kit (Merck Millipore, Taufkirchen, Germany) was used according to the manufacturer's protocol.
Measurment of cell differantiation	1 year	To determine gene expression levels, total RNA of SCAP was extracted using the Ambion PureLink RNA mini kit (Invitrogen, US) and the Roche cell RNA Kit (Penzberg, Germany) according to the manufacturer's instructions.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026